Insider Selling: Sunesis Pharmaceuticals major shareholder Sells 300,700 Shares of Stock (SNSS)
Sunesis Pharmaceuticals (NASDAQ:SNSS) major shareholder Bay City Capital Llc sold 300,700 shares of the stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $7.98, for a total value of $2,399,586.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Sunesis Pharmaceuticals (NASDAQ:SNSS) traded down 3.73% during mid-day trading on Friday, hitting $7.49. The stock had a trading volume of 1,901,954 shares. Sunesis Pharmaceuticals has a one year low of $3.84 and a one year high of $8.46. The stock’s 50-day moving average is $6.69 and its 200-day moving average is $6.05. The company’s market cap is $452.7 million.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last released its earnings data on Tuesday, August 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.03. The company had revenue of $2.00 million for the quarter, compared to the consensus estimate of $1.32 million. During the same quarter in the prior year, the company posted $0.18 earnings per share. The company’s quarterly revenue was up .0% on a year-over-year basis. Analysts expect that Sunesis Pharmaceuticals will post $-0.74 EPS for the current fiscal year.
Separately, analysts at Wedbush downgraded shares of Sunesis Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Friday.
Sunesis Pharmaceuticals, Inc (NASDAQ:SNSS) is a biopharmaceutical company focused on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers.
Receive News & Ratings for Sunesis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.